View Cancer Clinical Trials
A Study of Outcomes and Toxicity of Busulfex as Part of a High Dose Chemotherapy Preparative Regimen in Autologous Hematopoietic Stem Cell Transplantation for Patients with Plasma Cell Myeloma
|Blood & Marrow Transplant (BMT)
- Primary Objective:
- To compare relapse-free survival and overall survival between Busulfex and oral Busulfan when used for conditioning with cyclophosphamide in plasma cell myeloma patients undergoing autologous HSCT.
- Secondary Objectives:
- To compare pulmonary toxicity rates between Busulfex and oral Busulfan when used for conditioning with cyclophosphamide in plasma cell myeloma patients undergoing autologous HSCT.
- Patients with a diagnosis of plasma cell myeloma
- Patients with cardiac ejection fraction ≥ 45% or clearance by CCF cardiologist
- Patients with DLCO ≥ 45% predicted or clearance by CCF pulmonologist
- Patient with previously harvested peripheral blood progenitor cells with a minimum of 2 x 10^6 CD34+ cells/kg harvested
- Patient is greater than 18 years of age
- Patients receiving total body irradiation
- Non-myeloablative/reduced-intensity conditioning
- Pregnant or breast-feeding patients
- HIV positive
- Patient with Serum creatinine > 2.0
- Prior HSC transplant
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2014 Cleveland Clinic. All rights reserved.